July 2015_rev02

Clinical factsheet CF-02

Evaluation of the safety and efficacy of an investigation of EcoVag® as treatment of patients diagnosed with bacterial vaginosis.

— Dr. Viveka Gronlund, gynaecologist, Terveystalo Health Care Centers, Helsinki, Finland, June 1st, 2005

CONCLUSION

A majority of patients (80%) reported improvement of their symptoms of vaginal manifestations. The Improvements were in most cases obtained after 5-6 days
One out of 25 patients complained about a minor sideeffect.

FACTS

Study design:

The study was a typical trial performed in a special practice setting. The patients were investigated and were handed out 2 questionnaires before they commenced treatment. The 1st Patients coming to the clinics and suffering from mixed infection problems in the vagina i.e. bacterial vaginosis was recruited, investigated and treated accordingly. Patients were asked to complete a questionnaire before they started the treatment (questionnaire No. 1) and then commence treatment with lactobacillus (EcoVag®) for 8 days after which patients were asked to complete a new questionnaire (questionnaire No. 2) and forward both questionnaires to the clinics.

Patients were treated in a gynecological practice in 4 different places in Finland. The symptoms score were assessed by the patients from not at all troublesome (0) to very troublesome (4).

Subjects:

25 women, age between 18-70 years old. All suffering from mixed infection problems in vagina, typically considered as "problem patients" by the gynaecologist because they have had severe previous treatments.

Dosage:

1 EcoVag® OTC capsule per day containing minimum 10e8 CFU L. gasseri (Lba EB01-DSM 14869) and minimum 10e8 CFU L. rhamnosus (Lbp PB01-DSM 14870).

Duration:

8 days.



Figure 1:
Number of patients who find 1-2 days, 3-5 days or 5-8 days to improvement of vaginal manifestations